{"filings":[{"id":99530,"accession_number":"0001104659-26-055679","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theriva Biologics reports Q1 2026 net loss $2.0M, FDA agrees to Phase 3 design for VCN-01 in PDAC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $14.4M as of March 31, 2026; cash runway into Q1 2027.","FDA alignment on Phase 3 trial design for VCN-01 plus gemcitabine/nab-paclitaxel in metastatic PDAC.","New VIRAGE Phase 2b data at AACR 2026 shows improved OS and PFS across subgroups including liver metastases.","Compassionate use of VCN-01 in retinoblastoma started; Phase 2/3 trial expected first patient Dec 2026.","R&D expenses fell 88% to $355K as VIRAGE trial completed; G&A rose 43% to $2.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":300000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99529,"accession_number":"0001104659-26-044906","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva reports positive VIRAGE Phase 2b data for VCN-01 in pancreatic cancer at AACR 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VCN-01 + gemcitabine/nab-paclitaxel improved OS and PFS vs GnP alone in metastatic pancreatic cancer patients.","Later-emerging, higher magnitude, more durable responses observed; benefit maintained across subgroups including liver metastases.","Patients receiving a second VCN-01 dose showed greater OS and PFS benefit.","CEO reported alignment with FDA and EMA on proposed pivotal Phase 3 trial; planning study of more frequent VCN-01 dosing.","Data presented at AACR 2026 (poster CT162) on April 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99528,"accession_number":"0001104659-26-041507","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theriva Biologics fails to convene special meeting due to lack of quorum; will call new meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting on April 9, 2026 lacked quorum; meeting could not convene.","Company will call new meeting to seek approval for issuance of up to 16,184,560 shares upon exercise of New Warrants.","Under Inducement Agreement dated Oct 16, 2025, company must continue calling meetings every 60 days until approval or warrants expire.","Stockholders will receive new proxy materials with date/time of adjourned meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115586,"accession_number":"0001104659-26-033051","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics obtains FDA agreement on Phase 3 trial design for VCN-01 in metastatic PDAC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA provided general agreement on proposed Phase 3 trial design for VCN-01 plus gemcitabine/nab-paclitaxel.","Phase 3 trial will track successful VIRAGE Phase 2 design with repeat dosing and adaptive elements.","FDA agreed on primary endpoint (OS), key secondary endpoints, inclusion/exclusion criteria, and dosing schedule.","Consistent with prior EMA advice; company to finalize protocol and pursue funding or partnerships.","VIRAGE Phase 2 met primary endpoints; improved OS, PFS, DoR for VCN-01 plus SoC vs SoC alone in metastatic PDAC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115585,"accession_number":"0001104659-26-026765","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theriva Biologics FY2025 cash $13.1M; licensing deal, EMA guidance on VCN-01 Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["G&A expense rose 109% to $15.4M on $9.0M contingent consideration from VCN-01 trial success.","R&D expense fell 28% to $8.6M as VIRAGE Phase 2b completed; lower trial costs offset by patent spending.","Cash $13.1M at Dec 31, 2025; $15.2M at Feb 26, 2026 providing runway into Q1 2027.","Licensed SYN-020 to Rasayana for up to $38M milestones plus royalties; received $300K upfront.","EMA agreed on Phase 3 trial design for VCN-01 in PDAC; End-of-Phase 2 FDA meeting planned 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115584,"accession_number":"0001104659-26-016792","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Theriva Biologics licenses SYN-020 to Rasayana for $300K upfront, up to $38M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $300,000 received; eligible for $16M development/regulatory and $22M sales milestones.","Tiered single-digit royalties on net sales of SYN-020; Rasayana assumes all development and commercialization costs.","SYN-020 is an oral IAP enzyme with Phase 1 safety data; Rasayana plans Phase 2 testing.","Theriva to focus on lead pancreatic cancer program VCN-01 following out-license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115583,"accession_number":"0001104659-26-013907","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theriva Biologics special meeting fails due to no quorum; new meeting to seek warrant approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Feb 11, 2026 could not convene because a quorum was not present.","Company will call a new meeting to seek approval to issue up to 16,184,560 shares upon warrant exercise.","Under Inducement Agreement dated Oct 16, 2025, must call meetings every 60 days until approval or warrants expire.","New meeting date and proxy materials to be announced later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115582,"accession_number":"0001104659-26-002750","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theriva Biologics announces investor presentations with updated corporate deck","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company to present to investors over next several weeks; updated deck filed as Exhibit 99.1.","Presentation titled 'Unique Oncolytic Virus Therapies for Multiple Solid Tumors' dated Jan 2026.","CEO Steven Shallcross signed the filing; stock trades on NYSE American under TOVX.","No specific financial or clinical data disclosed in the filing or exhibit text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132017,"accession_number":"0001104659-25-124523","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"EMA provides positive Scientific Advice on Theriva's Phase 3 trial design for VCN-01 in metastatic PDAC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA CHMP agreed on Phase 3 design for VCN-01 + gem/nab-paclitaxel vs SoC; primary endpoint overall survival.","CHMP agreed on repeated dosing in macrocycles, enabling >2 doses; recognized VIRAGE survival benefit.","Theriva plans End-of-Phase 2 meeting with FDA in H1 2026 to finalize multinational Phase 3 trial.","Cash runway into Q1 2027 ($15.5M at Nov 10, 2025) supports regulatory activities and partnering.","VCN-01 has Orphan Drug designation in EU/US, Fast Track in US, and Rare Pediatric Disease for retinoblastoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132016,"accession_number":"0001104659-25-121246","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theriva Biologics special meeting fails due to lack of quorum; new meeting to be called","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting of Stockholders convened Dec. 15, 2025 lacked sufficient shares for quorum.","Company will call a new special meeting to seek stockholder approval for warrant exercise proposal.","Under Oct. 16, 2025 Inducement Agreement, company must hold meetings every 60 days until approval or warrants lapse.","Approval sought for issuance of up to 16,184,560 shares of common stock upon exercise of New Warrants.","Company will file and mail proxy materials for the new meeting, date and time to be announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132015,"accession_number":"0001104659-25-109821","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theriva Biologics Q3 2025 cash $7.5M; raises $8M post-quarter, extends runway into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $7.5M at Sep 30; subsequent raises bring to $15.5M at Nov 10, funding ops into Q1 2027.","Q3 R&D expense $2.6M (-7% YoY); G&A $1.9M (-18% YoY); workforce reduction implemented Sep 30.","VIRAGE Phase 2b data for VCN-01 in metastatic PDAC presented at ESMO; planning Phase 3 discussions with EMA/FDA.","Preclinical data for next-gen oncolytic virus VCN-12 showed improved cell killing and anti-tumor immunity vs VCN-01.","Retinoblastoma Phase 2/3 trial design in progress; regulatory discussion expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132014,"accession_number":"0001104659-25-103774","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theriva Biologics files $2.9M at-the-market equity offering through A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company filed a prospectus supplement for up to $2,894,225 of common stock in an ATM offering.","Sales agent is A.G.P./Alliance Global Partners; commission rate up to 3.0% of gross sales price.","Shares offered under existing effective S-3 registration statement (File No. 333-279077).","No arrangement for funds to be received in escrow; sales at market prices via commercial efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132013,"accession_number":"0001104659-25-102104","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theriva Biologics files prospectus supplement for up to $4.02M ATM offering of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $4,019,597 of common stock may be sold through A.G.P./Alliance Global Partners as sales agent.","Sales will be at-the-market under Rule 415(a)(4); agent receives up to 3% commission.","Shares offered under existing S-3 shelf (File No. 333-279077) effective September 25, 2024.","No minimum sales obligation; company retains discretion over timing and amount.","Legal opinion on share validity from Parsons Behle & Latimer filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132012,"accession_number":"0001104659-25-100608","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VIRAGE Phase 2b trial meets primary OS endpoint; VCN-01+SoC mOS 10.8 vs 8.6 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VCN-01 + gem/nab-paclitaxel met primary OS endpoint in FAS: median 10.8 vs 8.6 months, HR 0.57 (p=0.034).","PFS improved: 7.0 vs 4.6 months (HR 0.55, p=0.012) and duration of response doubled (11.2 vs 5.4 months).","Patients receiving 2 VCN-01 doses had greater OS benefit: median 14.8 vs 11.6 months (HR 0.44).","VCN-01 was safe and well tolerated; related SAEs were transient and resolved.","Data support further evaluation in larger blinded trial with additional VCN-01 doses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132011,"accession_number":"0001104659-25-100468","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Theriva (TOVX) raises ~$4.4M via warrant exercise at $0.54/share; grants 16.2M new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered warrant inducement with existing holders exercising 8,092,280 shares at $0.54 for ~$4.4M gross proceeds.","Issued new warrants for 16,184,560 shares (200% of exercised) at same $0.54 exercise price, exercisable 5 years from stockholder approval.","Net proceeds will be used for working capital; AGP served as financial advisor with 7% cash fee.","New warrants and underlying shares issued in private placement under Section 4(a)(2); resale registration to be filed within 30 days.","Company must seek stockholder approval for exercise of new warrants; meetings every 60 days if not obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132010,"accession_number":"0001104659-25-098882","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva VIRAGE Phase 2b: VCN-01+GA OS 10.8mo (HR0.57, p=0.055), PFS 7.0mo (HR0.55, p=0.011)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In FAS population, VCN-01 + GA improved median OS to 10.8 mo vs 8.6 mo (HR 0.57, p=0.055) and PFS to 7.0 vs 4.6 mo (HR 0.55, p=0.011).","Patients receiving 2 VCN-01 doses starting GA cycle 4 had OS 14.8 vs 11.6 mo (HR 0.44, p=0.046) and PFS 11.2 vs 7.4 mo (HR 0.48, p=0.017).","VCN-01 well tolerated; all 13 related serious adverse events resolved; common: flu-like symptoms (13.2%), transaminase increase (5.7%).","Data to be presented at ESMO 2025 mini oral session on Oct 20; abstract published. Study met primary endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132009,"accession_number":"0001104659-25-097739","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theriva Biologics unveils positive preclinical data for VCN-12, showing superiority over VCN-01","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VCN-12 showed up to 13.7x greater cytotoxicity than VCN-01 across multiple cancer cell lines in vitro.","In HP-1 pancreatic tumor hamster model, VCN-12 significantly reduced growth in both injected and non-injected tumors.","Complete tumor regression in 2/9 hamsters; those animals rejected tumor re-challenge 43 days later.","VCN-12 incorporates bee hyaluronidase (higher activity) and parasporin-2 to enhance immunogenic cell death.","Toxicity profile in mice similar to VCN-01; further preclinical studies planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132008,"accession_number":"0001104659-25-096946","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva presents preclinical data for VCN-12 oncolytic adenovirus at ESGCT congress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VCN-12, derived from VCN-01, armed with transgenes to improve tumor lysis, stroma degradation, and antitumor immune response.","Presentation at ESGCT 2025 in Seville, Spain on October 8, 2025, by co-founder Dr. Ramón Alemany.","Preclinical study published in Human Gene Therapy shows intracranial VCN-01 administration feasible for brain tumor treatment.","Study concludes findings provide strong rationale for VCN-01 development as therapy for brain tumors.","No financial guidance or material changes to business operations announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132007,"accession_number":"0001104659-25-096047","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Theriva Biologics cuts 32% of workforce, expects $520K severance costs, extends cash runway into Q2 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved restructuring plan to focus on business development and VCN-01 clinical trials for PDAC and retinoblastoma.","Workforce reduction of ~7 employees (32% of global workforce) implemented September 30, 2025.","Estimated $520K in cash severance and benefits charges in Q4 2025; expects ~$2M annual compensation savings.","Cash runway extended into Q2 2026 due to cost reductions and anticipated operating savings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148586,"accession_number":"0001104659-25-087465","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Theriva Biologics shareholders approve equity plan increase and elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amendment No. 3 to increase shares under 2020 Stock Incentive Plan from 2.5M to 4.5M.","All four director nominees elected: Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, Jeffrey Wolf.","Ratified BDO USA, P.C. as independent auditor for FY2025 with 3.61M votes for.","Advisory vote on executive compensation approved; future frequency set at three years.","Vote totals for each proposal are disclosed; broker non-votes totaled 2,212,112 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148585,"accession_number":"0001104659-25-075944","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theriva Biologics reports Q2 2025: VCN-01 Phase 2b success, cash $12.1M, runway into Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive topline from VIRAGE Phase 2b: VCN-01 plus chemo improved OS, PFS, DOR vs chemo alone in metastatic pancreatic cancer.","Cash and cash equivalents $12.1M as of June 30, 2025; early Aug cash $9.5M, expected runway into Q1 2026.","G&A expenses $11.2M (up 662% YoY) due to $9.2M contingent consideration adjustment from VIRAGE success; R&D $2.0M (down 34%).","Expanded VIRAGE data to be presented at ESMO 2025 Congress in October.","Phase 1 retinoblastoma data of VCN-01 presented at ASCO 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167441,"accession_number":"0001104659-25-062559","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theriva Biologics sets 2025 annual meeting for August 29; proxy deadlines revised","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for August 29, 2025; record date for voting is July 8, 2025.","Stockholder proposals under Rule 14a-8 must be received by July 5, 2025 for inclusion in proxy materials.","Director nominations or other proposals not seeking inclusion must be delivered by July 5, 2025.","Universal proxy rule compliance notice for director nominees also due by July 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167440,"accession_number":"0001104659-25-061203","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theriva Biologics files $2.5M at-the-market equity offering through A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $2,534,352 of common stock registered for sale via ATM method with A.G.P./Alliance Global Partners.","Sales agent commission rate set at up to 3.0% of gross proceeds per share sold.","No minimum sale requirement; agent uses commercially reasonable efforts on a principal or agency basis.","Proceeds will be used for general corporate purposes; no escrow or trust arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167439,"accession_number":"0001104659-25-055181","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics Phase 1 data: VCN-01 well-tolerated in retinoblastoma; eye preserved in 3 of 9 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VCN-01 intravitreal injection at 2E+10 vp/eye was well-tolerated; no retinal toxicity or DLTs; main AE Grade 1-2 uveitis.","Four of nine patients had improvement in vitreous seed density; 3 avoided enucleation with follow-up up to 49 months.","No Grade >=3 ocular or systemic toxicities; selective replication in tumor cells confirmed by immunohistochemistry.","RP2D defined as 2 doses of 2E+10 vp/eye; VCN-01 genomes in aqueous humor correlated with vitreous seed persistence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167438,"accession_number":"0001104659-25-048183","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theriva Biologics Q1 2025: VCN-01 Ph2b meets endpoints; cash runway extended into Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VCN-01 plus gemcitabine/nab-paclitaxel increased OS, PFS, DOR in mPDAC vs SoC alone in Phase 2b.","Two doses of VCN-01 showed greater OS benefit than one dose in patients receiving ≥4 chemo cycles.","Closed public offering of 6,818,180 shares and warrants at $1.10/unit, gross proceeds ~$7.5M.","Cash balance post-offering $14.1M, extending runway into Q1 2026.","Q1 2025 G&A $1.4M (-25% YoY); R&D $3.0M (-14% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167437,"accession_number":"0001104659-25-046170","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics closes $7.5M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$7.5M from offering of 6.8M shares (or pre-funded warrants) and common warrants at $1.10/unit.","Offering includes 1.99M shares, 4.83M pre-funded warrants, and 6.82M common warrants exercisable at $1.10 for 5 years.","Proceeds primarily for working capital, R&D, and manufacturing scale-up; no acquisition commitments.","Post-closing shares outstanding: 4,773,358 (excluding warrants).","A.G.P./Alliance Global Partners acted as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167436,"accession_number":"0001104659-25-045309","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Positive topline results from VIRAGE Phase 2b trial: VCN-01+SoC improves OS, PFS, DoR in metastatic pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS 10.8 vs 8.6 months for VCN-01+SoC vs SoC alone (HR=0.57, p=0.0546).","Median PFS 7.0 vs 4.6 months (HR=0.55, p=0.0105).","Median DoR doubled to 11.2 vs 5.4 months (HR=0.22, p=0.0035).","2-dose VCN-01 + ≥4 cycles SoC subgroup: median OS 14.8 vs 11.6 months (HR=0.44, p=0.046).","Safety met primary endpoint; AEs transient/reversible, consistent with prior trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184738,"accession_number":"0001104659-25-029654","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics: second IDMC review finds VCN-01 well tolerated in metastatic PDAC trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC reviewed safety data from 101 patients across 14 sites in US and Spain.","VCN-01 AE profile consistent with prior trials; AEs transient and reversible, less frequent after second dose.","Patient enrollment completed Sep 2024; topline clinical outcomes data expected Q2 2025.","CEO says positive data, along with prior FDA/EMA feedback, could guide Phase 3 registrational trial design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184737,"accession_number":"0001104659-25-021379","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theriva Biologics FY2024 cash $11.6M; VCN-01 Phase 2b data due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $11.6M as of Dec 31, 2024; expected runway into Q3 2025.","R&D expenses decreased 16% to $12.0M; G&A expenses increased 4% to $7.4M.","VIRAGE Phase 2b enrollment completed (92 evaluable patients); topline data expected Q2 2025.","FDA Fast Track for VCN-01 in PDAC; FDA and EMA provided Phase 3 trial design guidance.","Audited 10-K includes going concern explanatory paragraph from independent auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201318,"accession_number":"0001104659-24-125774","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics receives FDA guidance for Phase 3 study of VCN-01 in metastatic pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA advised stand-alone Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel; VIRAGE Phase 2b should not be expanded into Phase 3.","FDA generally agreed with Theriva's proposed Phase 3 design; no additional chemotherapy needed for PDAC.","VIRAGE Phase 2b enrollment completed; final patient follow-up is underway.","Additional FDA meeting planned after VIRAGE completion to discuss Phase 3 protocol details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201317,"accession_number":"0001104659-24-116420","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theriva Biologics Q3 2024: completes VIRAGE enrollment, cash $16.4M, impairment charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment of 92 evaluable patients in VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma.","Cash and cash equivalents totaled $16.4M at Sep 30, 2024, down from $23.2M at Dec 31, 2023.","R&D expenses decreased 32% to $2.7M; G&A expenses increased to $2.3M partly due to contingent consideration adjustments.","Recorded impairment charges of $1.3M on in-process R&D and $1.5M on goodwill due to decline in stock price.","Discussions initiated with regulators to potentially expand VIRAGE into Phase 3 registrational trial; also positive progress in retinoblastoma program."],"consensus_eps_estimate":null,"consensus_eps_actual":-24.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201316,"accession_number":"0001104659-24-113480","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Theriva shareholders approve 8.9x stock plan share increase and 25x authorized share increase.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amendment No. 2 to the 2020 Stock Incentive Plan, increasing the share reserve from 280,000 to 2,500,000 shares.","Non-employee director annual grant limit raised from 40,000 to 250,000 shares under the amended plan.","Certificate of Change filed to increase authorized common shares from 14,000,000 to 350,000,000, effective November 1, 2024.","All four director nominees elected; BDO USA, P.C. ratified as independent auditor for FY2024.","Shareholders also approved the adjournment proposal, but it was not needed as quorum was present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201315,"accession_number":"0001104659-24-108958","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"European Commission grants orphan designation to VCN-01 for retinoblastoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Orphan medicinal product designation granted by European Commission for VCN-01 oncolytic adenovirus to treat retinoblastoma.","FDA previously granted orphan drug and rare pediatric disease designations for same indication.","Designation provides 10-year EU market exclusivity post-approval, protocol assistance, and fee reductions.","Phase 1 trial in pediatric refractory retinoblastoma showed encouraging safety/activity with intravitreal VCN-01.","Company working with physicians and regulators on VCN-01 as adjunct to chemotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201314,"accession_number":"0001104659-24-105634","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics DSMC recommends advancing SYN-004 trial to Cohort 3 after positive Cohort 2 safety data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMC reviewed safety and PK data from Cohort 2 (19 patients) and recommended study proceed to Cohort 3 using cefepime.","No SAEs or AEs determined related to study drug; 15 SAEs reported among 10 patients typical for allo-HCT.","No patient blood samples positive for SYN-004 at any timepoint; piperacillin PK as expected.","Company pursuing additional funding to enable Cohort 3 conduct; Phase 1b/2a trial remains blinded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217352,"accession_number":"0001104659-24-103813","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics closes $2.5M public offering of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate gross proceeds of approximately $2.5 million from offering of common shares and warrants.","Pricing at $1.75 per share and accompanying warrant; warrants exercisable at $2.00 per share for five years.","Post-offering outstanding shares: 2,272,462; proceeds for working capital, R&D, and manufacturing scale-up.","A.G.P./Alliance Global Partners served as placement agent with 7% fee plus expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217351,"accession_number":"0001104659-24-101892","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics achieves target enrollment of 92 patients in VIRAGE Phase 2b trial for VCN-01 in pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Target enrollment of 92 evaluable patients (46 per arm) achieved across 15 sites in Spain and USA within 21 months.","VCN-01 is a systemically-administered oncolytic adenovirus with FDA Orphan Drug and Fast Track Designations for metastatic PDAC.","VCN-01 treatment arm: two IV doses (1x10^13 vp/patient) administered ~3 months apart, 7 days prior to gem/nab-paclitaxel cycles.","Phase 1 data for single VCN-01 dose plus SoC (n=6): 83% overall response rate, median PFS 6.3 months, OS 20.8 months.","Company plans regulatory engagements to discuss next steps, including potential interim data analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217350,"accession_number":"0001104659-24-100010","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["2.03","8.01","7.01","9.01"],"status":"ready","headline":"Theriva Biologics awarded €2.28M Spanish government funding for THERICEL cell platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["€1.33M unsecured loan lump sum in Q4 2024; interest 4.015%; repayable over 7 yrs after 3-yr grace.","€0.95M grant to Universitat Autònoma de Barcelona paid in annual installments over 3 years.","Funds to advance suspension cell platform for adenovirus/AAV therapies; scaling VCN-01 production.","Award validates proprietary A549 suspension cell platform for clinical manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217349,"accession_number":"0001104659-24-098225","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theriva Biologics issues 27,316 common shares upon conversion of Series C and D preferred stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4,138 Series C shares converted into 1,086 common shares at $30.50 per share.","100,000 Series D shares converted into 26,230 common shares at $30.50 per share.","Total 27,316 common shares issued; no Series C or D preferred shares remain outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217348,"accession_number":"0001104659-24-092644","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Theriva Biologics effects 1-for-25 reverse stock split to meet NYSE American price rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-25; shares reduced from 25,131,230 to approximately 1,005,249.","Effective 12:01 a.m. ET on August 26, 2024; trading began on post-split basis same day.","No fractional shares issued; holders otherwise entitled to fractional shares receive rounding up to next whole share.","Exercise price and share count under options, warrants, and equity plans adjusted proportionately.","Trading symbol unchanged ('TOVX'); new CUSIP number is 87164U508."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217347,"accession_number":"0001104659-24-090522","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Theriva Biologics announces 1-for-25 reverse stock split effective Aug 26, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-25 ratio; outstanding shares reduce from ~25.1M to ~1.0M.","Effective 12:01 a.m. ET on Aug 26, 2024; trading on split-adjusted basis same day.","Split intended to meet NYSE American per-share price listing requirements.","No fractional shares issued; holders of fractional shares get rounded up to next whole share.","CUSIP changes to 87164U 508; ticker remains TOVX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217346,"accession_number":"0001104659-24-088680","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theriva Biologics Q2 2024 cash $16.6M, VIRAGE trial to complete enrollment in Q3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $16.6M as of June 30, 2024 vs $23.2M at Dec 31, 2023; runway into Q2 2025.","VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.","FDA granted Fast Track Designation for VCN-01 in metastatic pancreatic adenocarcinoma.","Goodwill impairment of $4.0M recorded due to stock price decline and increased discount rate.","R&D expenses $3.0M, G&A $1.5M for Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217345,"accession_number":"0001104659-24-084159","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics receives FDA Rare Pediatric Drug Designation for VCN-01 in retinoblastoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants Rare Pediatric Drug Designation for VCN-01, a stroma-degrading oncolytic adenovirus, to treat retinoblastoma.","Prior orphan drug designation for same indication; RPDD may provide a Priority Review Voucher upon BLA approval.","Holders of Series C Convertible Preferred Stock converted 135,431 shares into 888,072 common shares at $1.22 per share.","Positive Phase 1 results from investigator-sponsored trial of intravitreal VCN-01 in pediatric refractory retinoblastoma inform clinical pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237177,"accession_number":"0001104659-24-064544","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Theriva Biologics receives FDA Fast Track Designation for VCN-01 in metastatic pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for VCN-01 combined with gemcitabine/nab-paclitaxel for metastatic pancreatic adenocarcinoma.","VCN-01 is being evaluated in the ongoing Phase 2b VIRAGE trial as first-line therapy for pancreatic ductal adenocarcinoma.","Enrollment in VIRAGE expected to complete in Q3 2024.","Previously, FDA granted orphan drug designation to VCN-01 for PDAC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237176,"accession_number":"0001104659-24-062270","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theriva Biologics receives conversion notice for 135,431 Series C Preferred shares into ~888K common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder converted 135,431 Series C Preferred shares into 888,072 common shares at $1.22 per share.","Conversion increases outstanding common shares by approximately 888,000, diluting existing shareholders.","Notice received May 13, 2024; conversion effective upon notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237175,"accession_number":"0001104659-24-057689","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theriva Biologics reports $18.3M cash as of Q1 2024, VIRAGE enrollment on track for Q3 completion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $18.3M at March 31, 2024, expected to fund operations into Q1 2025.","R&D expenses $3.5M in Q1 2024, up 16% YoY due to clinical trial costs.","VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.","Positive topline data from Phase 1 trial of VCN-01 in pediatric refractory retinoblastoma – study committee deemed results positive.","Licensing discussions ongoing for SYN-020 intestinal alkaline phosphatase asset."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237174,"accession_number":"0001104659-24-056146","cik":894158,"company_name":"Theriva Biologics, Inc.","ticker":"TOVX","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Theriva Biologics amends ATM sales agreement with A.G.P., terminates B. Riley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Amendment No. 2 to At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners on May 2, 2024.","Amendment updates registration statement to new Form S-3 filed May 2, 2024 for future at-the-market offerings.","B. Riley Securities, Inc. agreed to termination as party to the Sales Agreement effective May 1, 2024.","Other terms of the original agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13506211.800000003,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}